Item 3.02 Unregistered Sales of Equity Securities.
On January 6, 2023, 2seventy bio, Inc. (the "Company") entered into a Share
Purchase Agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron") pursuant
to which the Company sold 1,114,827 shares of its common stock, par value
$0.0001 per share, to Regeneron for an aggregate cash price of approximately $20
million, or $17.94 per share. The offer, sale, and issuance of shares is exempt
from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as
amended, as a transaction by an issuer not involving a public offering.
Item 8.01 Other Events.
On January 6, 2023, the Company announced an amendment to its collaboration with
Regeneron that will facilitate an expanded and accelerated development plan for
novel cell therapy-based combinations for solid tumors. The collaboration will
leverage the Company's platform for T cell therapy research and development with
Regeneron's antibodies and bispecifics. A copy of the press release is being
filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by
reference herein.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit
No. Description
99.1 Press release issued by 2seventy bio, Inc. on January 6, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document
and incorporated as Exhibit 101)
____________
© Edgar Online, source Glimpses